The trademark application Baricitinib was filed by Eli Lilly and Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on January 13, 2021, and still open for oppositions.
The application was filed in English (Italian was selected as the second language).
Appointment and Replacement of representative of the trademark registration was recorded on November 23, 2020.